Effects of St. John's Wort on irinotecan metabolism

Journal of the National Cancer Institute

Volumn 94, Issue 16, 2002, Pages 1247-1249

  Mathijssen, Ron H J ^a   Verweij, Jaap ^a   De Bruijn, Peter ^a   Loos, Walter J ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CYTOCHROME P450 3A4; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; ISOENZYME;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; HYPERICUM PERFORATUM; LUNG CANCER; MALE; METHODOLOGY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; STUDENT T TEST; TREATMENT OUTCOME;

EID: 0037151365     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.16.1247     Document Type: Article

References (23)

1. A primer of complementary and alternative medicine commonly used by cancer patients
2. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: A randomized, controlled study in mild-moderate depression
3. Hypericum for depression. An update of the clinical evidence
4. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum)
5. Acute heart transplant rejection due to Saint John's wort
6. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum)
7. Indinavir concentrations and St. John's wort
8. Second thoughts about safety of St. John's wort
9. St. John's Wort: Effect on CYP3A4 activity
10. St. John's Wort induces intestinal P-glycoprotein and hepatic CYP3A4
11. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
12. Irinotecan (CPT-11) metabolism and disposition in cancer patients
13. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
14. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4
15. Pharmacokinetics of irinotecan (IRN) and metabolites in pediatric high-grade glioma patients with and without co-administration of enzyme-inducing anticonvulsants
16. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
17. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers
18. Lack of effect of St. John's Wort on carbamazepine pharmacokinetics in healthy volunteers
19. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice
20. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report
21. Irinotecan therapy in adults with recurrent or progressive malignant glioma
22. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma